-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Piper Sandler Trims Replimune Group (NASDAQ:REPL) Target Price to $43.00
Piper Sandler Trims Replimune Group (NASDAQ:REPL) Target Price to $43.00
Replimune Group (NASDAQ:REPL – Get Rating) had its target price reduced by Piper Sandler to $43.00 in a report released on Monday, Stock Target Advisor reports.
REPL has been the subject of a number of other reports. SVB Leerink reduced their price objective on shares of Replimune Group from $48.00 to $37.00 and set an outperform rating for the company in a research note on Friday, August 5th. HC Wainwright reaffirmed a buy rating and issued a $60.00 target price on shares of Replimune Group in a report on Tuesday, May 24th. Finally, Wedbush lowered their target price on shares of Replimune Group from $59.00 to $52.00 and set an outperform rating on the stock in a report on Tuesday, May 24th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $45.86.
Get Replimune Group alerts:Replimune Group Stock Up 0.2 %
REPL stock opened at $20.68 on Monday. Replimune Group has a 52 week low of $13.05 and a 52 week high of $35.93. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -8.24 and a beta of 1.98. The firm's 50-day moving average is $19.27 and its two-hundred day moving average is $17.40. The company has a current ratio of 19.79, a quick ratio of 19.79 and a debt-to-equity ratio of 0.06.
Replimune Group (NASDAQ:REPL – Get Rating) last released its earnings results on Thursday, August 4th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.15). On average, analysts forecast that Replimune Group will post -2.99 earnings per share for the current fiscal year.Institutional Investors Weigh In On Replimune Group
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Amalgamated Bank bought a new position in shares of Replimune Group in the first quarter worth $76,000. Quantbot Technologies LP lifted its stake in Replimune Group by 498.0% in the second quarter. Quantbot Technologies LP now owns 5,980 shares of the company's stock valued at $104,000 after buying an additional 4,980 shares during the period. BNP Paribas Arbitrage SA lifted its stake in Replimune Group by 157.6% in the second quarter. BNP Paribas Arbitrage SA now owns 6,391 shares of the company's stock valued at $112,000 after buying an additional 3,910 shares during the period. Point72 Hong Kong Ltd increased its holdings in shares of Replimune Group by 369.7% during the first quarter. Point72 Hong Kong Ltd now owns 6,919 shares of the company's stock valued at $117,000 after acquiring an additional 5,446 shares in the last quarter. Finally, Virtus ETF Advisers LLC increased its holdings in shares of Replimune Group by 25.9% during the second quarter. Virtus ETF Advisers LLC now owns 7,108 shares of the company's stock valued at $124,000 after acquiring an additional 1,461 shares in the last quarter. Institutional investors and hedge funds own 75.42% of the company's stock.
Replimune Group Company Profile
(Get Rating)
Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.
Further Reading
- Get a free copy of the StockNews.com research report on Replimune Group (REPL)
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
- Is PayPal A Buy After Post-Earnings Price Jump?
- Williams-Sonoma's High-End Consumers Are Still Spending
- Snowflake Stock Soars On Strong Results
- ShockWave Stuns With 40% Post-Earnings Price Move: Is It A Buy?
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
Replimune Group (NASDAQ:REPL – Get Rating) had its target price reduced by Piper Sandler to $43.00 in a report released on Monday, Stock Target Advisor reports.
據Stock Target Advisor報道,週一發佈的一份報告中,派珀·桑德勒將Replimune Group(納斯達克代碼:REPL-GET Rating)的目標價下調至43美元。
REPL has been the subject of a number of other reports. SVB Leerink reduced their price objective on shares of Replimune Group from $48.00 to $37.00 and set an outperform rating for the company in a research note on Friday, August 5th. HC Wainwright reaffirmed a buy rating and issued a $60.00 target price on shares of Replimune Group in a report on Tuesday, May 24th. Finally, Wedbush lowered their target price on shares of Replimune Group from $59.00 to $52.00 and set an outperform rating on the stock in a report on Tuesday, May 24th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $45.86.
REPL一直是其他一些報告的主題。SVB Leerink將Replimune Group的股票目標價從48.00美元下調至37.00美元,並在8月5日星期五的一份研究報告中為該公司設定了表現優於大盤的評級。在5月24日週二的一份報告中,HC Wainwright重申了買入評級,併發布了Replimune Group股票的目標價60.00美元。最後,韋德布什在5月24日週二的一份報告中將Replimune Group的目標價從59.00美元下調至52.00美元,並對該股設定了表現優於大盤的評級。根據MarketBeat.com的數據,七位股票研究分析師對該股的評級為買入,目前該股的共識評級為買入,共識目標價為45.86美元。
Replimune Group Stock Up 0.2 %
Replimune Group股價上漲0.2%
REPL stock opened at $20.68 on Monday. Replimune Group has a 52 week low of $13.05 and a 52 week high of $35.93. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -8.24 and a beta of 1.98. The firm's 50-day moving average is $19.27 and its two-hundred day moving average is $17.40. The company has a current ratio of 19.79, a quick ratio of 19.79 and a debt-to-equity ratio of 0.06.
REPL股票週一開盤報20.68美元。Replimune Group的52周低點為13.05美元,52周高點為35.93美元。該公司市值為10.2億美元,市盈率為-8.24倍,貝塔係數為1.98。該公司的50日移動均線切入位為19.27美元,200日移動均線切入位為17.40美元。該公司的流動比率為19.79,速動比率為19.79,債務權益比率為0.06。
Institutional Investors Weigh In On Replimune Group
機構投資者看好Replimune Group
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Amalgamated Bank bought a new position in shares of Replimune Group in the first quarter worth $76,000. Quantbot Technologies LP lifted its stake in Replimune Group by 498.0% in the second quarter. Quantbot Technologies LP now owns 5,980 shares of the company's stock valued at $104,000 after buying an additional 4,980 shares during the period. BNP Paribas Arbitrage SA lifted its stake in Replimune Group by 157.6% in the second quarter. BNP Paribas Arbitrage SA now owns 6,391 shares of the company's stock valued at $112,000 after buying an additional 3,910 shares during the period. Point72 Hong Kong Ltd increased its holdings in shares of Replimune Group by 369.7% during the first quarter. Point72 Hong Kong Ltd now owns 6,919 shares of the company's stock valued at $117,000 after acquiring an additional 5,446 shares in the last quarter. Finally, Virtus ETF Advisers LLC increased its holdings in shares of Replimune Group by 25.9% during the second quarter. Virtus ETF Advisers LLC now owns 7,108 shares of the company's stock valued at $124,000 after acquiring an additional 1,461 shares in the last quarter. Institutional investors and hedge funds own 75.42% of the company's stock.
一些對衝基金和其他機構投資者最近調整了對該公司的持股。合併銀行在第一季度購買了Replimune Group價值7.6萬美元的新股票頭寸。Quantbot Technologies LP在第二季度增持了Replimune Group 498.0%的股份。Quantbot Technologies LP現在擁有5980股該公司股票,價值10.4萬美元,在此期間又購買了4980股。法國巴黎銀行套利公司在第二季度增持了Replimune集團157.6%的股份。法國巴黎銀行套利公司現在持有該公司6,391股股票,價值11.2萬美元,在此期間又購買了3,910股。Point72 Hong Kong Ltd於第一季增持Replimune Group股份369.7%。Point72 Hong Kong Ltd在上個季度增持了5,446股後,目前持有該公司6919股股票,價值11.7萬美元。最後,Virtus ETF Advisers LLC在第二季度增持了25.9%的Replimune Group股票。Virtus ETF Advisers LLC在上個季度增持了1,461股後,現在擁有該公司7,108股股票,價值12.4萬美元。機構投資者和對衝基金持有該公司75.42%的股票。
Replimune Group Company Profile
複製集團公司簡介
(Get Rating)
(獲取評級)
Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.
Replimune Group,Inc.是一家生物技術公司,開發治療癌症的溶瘤免疫基因療法。它使用其專有的免疫療法平臺來設計和開發旨在激活免疫系統對抗癌症的候選產品。該公司的主要候選產品是RP1,這是單純皰疹病毒1型的選擇性複製版本,目前正處於針對一系列實體腫瘤的I/II期臨牀試驗,以及針對皮膚鱗狀細胞癌患者的II期臨牀試驗。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Replimune Group (REPL)
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
- Is PayPal A Buy After Post-Earnings Price Jump?
- Williams-Sonoma's High-End Consumers Are Still Spending
- Snowflake Stock Soars On Strong Results
- ShockWave Stuns With 40% Post-Earnings Price Move: Is It A Buy?
- 免費獲取StockNews.com關於Replimune Group的研究報告(REPL)
- 艾伯維公司。應該在你的股息投資組合中佔有一席之地嗎?
- PayPal是盈利後價格跳漲後的買入嗎?
- 威廉姆斯-索諾馬的高端消費者仍在消費
- 雪花股票因業績強勁而飆升
- 股價下跌40%的Shockwave Stunts:這是買入嗎?
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受Replimune Group Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收Replimune Group和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧